var data={"title":"Nitric oxide: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Nitric oxide: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6660?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=nitric-oxide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Nitric oxide: Patient drug information&quot;</a> and <a href=\"topic.htm?path=nitric-oxide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitric oxide: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201946\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>INOmax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201947\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>INOmax;</li>\n      <li>Noxivent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201958\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vasodilator, Pulmonary</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7730323\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute vasodilator testing in pulmonary artery hypertension (off-label use) (McLaughlin 2009): </b> Inhalation: 10 to 80 parts per million (ppm) for 5 minutes; commonly used doses: 20 to 40 ppm. <b>Note:</b> Measure hemodynamics while on nitric oxide. Doses above 20 ppm should be used with caution; doses &gt;40 ppm provide minimal additional clinical benefit. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Right ventricular dysfunction after cardiac surgery (off-label use): </b>Usual dose: 20 ppm via mechanical ventilation circuit; dosage range: 5 to 20 ppm (Argenziano 1998; Costanzo 2010; Mosquera 2002; Paniagua 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201952\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=nitric-oxide-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Nitric oxide: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypoxic respiratory failure associated with pulmonary hypertension:</b> Neonates (&gt;34 weeks gestational age): Inhalation: 20 parts per million (ppm); maintain treatment up to 14 days or until resolution of oxygen desaturation; doses &gt;20 ppm are not recommended due to the risk of methemoglobinemia and pulmonary injury from elevated NO<sub>2</sub>. Abrupt discontinuation may lead to worsening oxygenation and rebound pulmonary hypertension; to avoid rebound wean nitric oxide. To wean nitric oxide, titrate down in several steps (pause several hours at each step); monitor for hypoxemia. Various weaning methods have been used in clinical trials and no standard wean exists; some have suggested weaning by 5 to 10 ppm every 4 hours until the patient is stable at 5 ppm; once stable at 5 ppm, the dose should be decreased by 1 ppm every 4 hours and discontinued at 1 ppm if the patient remains well oxygenated. If deterioration occurs during weaning or after discontinuation, increase nitric oxide to the previous dose or restart; once improved, wean more slowly (Peliowski 2012; Ware 2015). <b>Note:</b> Use in preterm neonates is not recommended; nitric oxide therapy does not improve survival in preterm neonates (&lt;34 weeks) with respiratory failure and evidence does not support using in these patients to prevent bronchopulmonary dysplasia (BPD), severe intraventricular hemorrhage (IVH), or other neonatal morbidities (AAP [Kumar 2014]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210501\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20210502\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201929\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gas, for inhalation: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 100 ppm (1963 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 1918 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 100 ppm (353 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 344 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 800 ppm (1963 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 1918 L]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">INOmax: 800 ppm (353 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 344 L]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201914\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49192472\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gas, for inhalation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kinox: 100 ppm (2138 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 2091 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kinox: 100 ppm (362 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 351 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kinox: 800 ppm (2138 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 2091 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Kinox: 800 ppm (362 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 351 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noxivent: 100 ppm (2237 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 2196 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noxivent: 100 ppm (348 L) [nitric oxide 0.01% and nitrogen 99.99%; delivers 341 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noxivent: 800 ppm (2239 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 2197 L]</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Noxivent: 800 ppm (348 L) [nitric oxide 0.08% and nitrogen 99.92%; delivers 341 L]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201931\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Inhalation: Administration of nitric oxide should be done by a health care professional who has completed a comprehensive training program. INOmax may only be administered using a calibrated INOmax DS<sub>IR</sub> nitric oxide delivery systems. Only validated ventilator systems should be used with nitric oxide. To prevent treatment interruptions (power and system failures), immediate access to a backup battery power supply and an independent reserve nitric oxide delivery system is essential. Do not abruptly discontinue; must wean. To wean nitric oxide, titrate down in several steps, pausing several hours before reducing further; monitor for hypoxemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201930\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Hypoxic respiratory failure associated with pulmonary hypertension in neonates:</b> Treatment of term and near-term (&gt;34 weeks gestational age) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension to improve oxygenation and reduce the need for extracorporeal membrane oxygenation. Used in conjunction with ventilatory support and other agents.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730874\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute vasodilator testing in pulmonary arterial hypertension; Right ventricular dysfunction after cardiac surgery; Adult respiratory distress syndrome (ARDS)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201921\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Cardiovascular: Hypotension (14%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Postmarketing and/or case reports: Hypoxemia, methemoglobinemia, pulmonary edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Note:</b> Occupational exposure (eg, hospital staff) may result in chest discomfort, dizziness, dry throat, dyspnea, and headache.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201934\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Neonates dependent on right-to-left shunting of blood</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201918\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull;Airway injury: May result from inflammation and lung tissue damage caused by nitrogen dioxide (NO<sub>2</sub>) formed in nitric oxide and oxygen gas mixtures. If there is an unexpected change in NO<sub>2</sub> concentration, or if NO<sub>2</sub> concentration in the breathing circuit reaches 3 ppm, assess delivery system and recalibrate the NO<sub>2</sub> analyzer; adjust dose of nitric oxide and/or FiO<sub>2</sub> as appropriate. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Methemoglobinemia: Dose-related methemoglobin (when nitric oxide combines with hemoglobin) may occur and lead to hypoxemia; monitor methemoglobin concentrations within 4 to 8 hours of starting nitric oxide treatment and then periodically; optimize oxygenation by adjusting nitric oxide dose as necessary. If methemoglobin levels do not resolve with decrease in dose or discontinuation of nitric oxide, additional therapy may be warranted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Heart failure (HF): Use in patients with left ventricular dysfunction may increase pulmonary capillary wedge pressure, worsen left ventricular dysfunction, and cause pulmonary edema, systemic hypotension, bradycardia, and cardiac arrest; discontinue nitric oxide and provide symptomatic care.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary artery hypertension (PAH) : Acute vasodilator testing (not an approved use): Use with extreme caution in patients with concomitant heart failure (LV systolic dysfunction with significantly elevated left heart filling pressures) or pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis; significant decompensation has occurred resulting in acute pulmonary edema.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Abrupt discontinuation: Avoid abrupt discontinuation; may lead to worsening oxygenation, and increasing pulmonary artery pressure (PAP) (ie, rebound pulmonary hypertension syndrome). Signs and symptoms of rebound pulmonary hypertension syndrome include hypoxemia, systemic hypotension, bradycardia, and reduced cardiac output; reinitiate nitric oxide immediately if this occurs. In order to wean, titrate down in many steps (pause several hours at each step) and monitor for hypoxemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Doses above 20 ppm should not be used (or should be used with caution [off-label dosing]) because of the increased risk of methemoglobinemia and elevated levels of nitrogen dioxide (NO<sub>2</sub>), a toxic metabolite. Methemoglobin concentrations and inspired NO<sub>2</sub> should be monitored.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Lack of response: Worsening oxygenation and increasing PAP may occur in patients who do not respond.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299766\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201923\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9447&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dapsone (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methemoglobinemia Associated Agents: Nitric Oxide may enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when nitric oxide is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prilocaine: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia.  Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia.  Avoid lidocaine/prilocaine in infants receiving such agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Nitrite: Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracaine (Topical): May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201925\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201937\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Nitric oxide is not indicated for use in adults. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201938\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if nitric oxide is excreted in breast milk. Nitric oxide is not indicated for use in adults.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201927\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Respiratory status including arterial blood gases with close attention to PaO<sub>2</sub>, methemoglobin (measured within 4 to 8 hours after initiation and periodically throughout treatment), inspired NO<sub>2</sub>, vital signs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201917\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">In neonates with persistent pulmonary hypertension, nitric oxide improves oxygenation. Nitric oxide relaxes vascular smooth muscle by binding to the heme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3',5'-monophosphate, which leads to vasodilation. When inhaled, pulmonary vasodilation occurs and an increase in the partial pressure of arterial oxygen results. Dilation of pulmonary vessels in well ventilated lung areas redistributes blood flow away from lung areas where ventilation/perfusion ratios are poor.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201933\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Systemic after inhalation </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Nitric oxide combines with hemoglobin that is 60% to 100% oxygenated. Nitric oxide combines with oxyhemoglobin to produce methemoglobin and nitrate. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite respectively, which interact with oxyhemoglobin to then produce methemoglobin and nitrate. At 80 ppm the methemoglobin percent is ~5% in neonates after 8 hours of administration; methemoglobin levels &gt;7% were attained only in neonates receiving 80 ppm. Doses &gt;20 ppm are not recommended for use in neonatal patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F201939\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>INOflo (JP);</li>\n      <li>INOmax (AT, AU, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IS, IT, LT, MT, NL, NO, PL, PT, RO, SE, SG, SK);</li>\n      <li>Neophyr (IE);</li>\n      <li>Nomixgen (NL);</li>\n      <li>Noxap (CZ, ES, FR, NL, PT);</li>\n      <li>Pulmonox (FI);</li>\n      <li>Solcogyn (QA);</li>\n      <li>VasoKINOX (BE, DK, ES, PT)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics, Committee on Fetus and Newborn, &ldquo;Use of Inhaled Nitric Oxide,&rdquo; <i>Pediatrics</i>, 2000, 106(2 Pt 1):344-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/10920164/pubmed\" target=\"_blank\" id=\"10920164\">10920164</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9485226\"></a>Argenziano M, Choudhri AF, Moazami N, et al, &quot;Randomized, Double-Blind Trial of Inhaled Nitric Oxide in LVAD Recipients With Pulmonary Hypertension,&quot; <i>Ann Thorac Surg</i>, 1998, 65(2):340-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/9485226/pubmed\" target=\"_blank\" id=\"9485226\">9485226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Costanzo MR, Dipchand A, Starling R, et al, &quot;The International Society of Heart and Lung Transplantation Guidelines for the Care of Heart Transplant Recipients,&quot; <i>J Heart Lung Transplant</i>, 2010, 29(8):914-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/20643330/pubmed\" target=\"_blank\" id=\"20643330\">20643330</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davidson D, Barefield ES, Kattwinkel J, et al, &ldquo;Inhaled Nitric Oxide for the Early Treatment of Persistent Pulmonary Hypertension of the Term Newborn: A Randomized, Double-Masked, Placebo-Controlled, Dose-Response, Multicenter Study: I-NO/PPHN Study Group.&rdquo; <i>Pediatrics</i>, 1998, 101(3 Pt 1):325-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/9480993/pubmed\" target=\"_blank\" id=\"9480993\">9480993</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gali&egrave; N, Corris PA, Frost A, et al. Updated treatment algorithm of pulmonary arterial hypertension. <i>J Am Coll Cardiol</i>. 2013;62(25 Suppl):D60-D72. doi: 10.1016/j.jacc.2013.10.031.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/24355643/pubmed\" target=\"_blank\" id=\"24355643\">24355643</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Inhaled Nitric Oxide in Full-Term and Nearly Full-term Infants With Hypoxic Respiratory Failure.&rdquo; The Neonatal Inhaled Nitric Oxide Study Group, <i>N Engl J Med</i>, 1997, 336(9):597-604.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/9036320/pubmed\" target=\"_blank\" id=\"9036320\">9036320</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    INOmax (nitric oxide) [prescribing information]. Hazelwood, MO: INO Therapeutics; October 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    INOmax (nitric oxide) [product monograph]. Ontario, Canada: Mallinckrodt Manufacturing; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kinox (nitric oxide) [product monograph]. Brampton, Ontario, Canada: VitalAire Canada Inc; December 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P; Committee on Fetus and Newborn; American Academy of Pediatrics. Use of inhaled nitric oxide in preterm infants. <i>Pediatrics</i>. 2014;133(1):164-170. doi: 10.1542/peds.2013-3444.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/24379225/pubmed\" target=\"_blank\" id=\"24379225\">24379225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    McLaughlin VV, Archer SL, Badesch DB, et al, &ldquo;ACCF/AHA 2009 Expert Consensus Document on Pulmonary Hypertension. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association,&rdquo; <i>Circulation</i>, 2009, 119(16):2250-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/19332472/pubmed\" target=\"_blank\" id=\"19332472\">19332472</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11959233\"></a>Mosquera I, Crespo-Leiro MG, Tabuyo T, et al, &quot;Pulmonary Hypertension and Right Ventricular Failure After Heart Transplantation: Usefulness of Nitric Oxide,&quot; <i>Transplant Proc</i>, 2002, 34(1):166-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/11959233/pubmed\" target=\"_blank\" id=\"11959233\">11959233</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Noxivent (nitric oxide) [product monograph]. Mississauga, Ontario, Canada: Praxair Canada Inc; January 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"10500690\"></a>Paniagua MJ, Crespo-Leiro MG, Rodr&iacute;guez JA, et al, &quot;Usefulness of Nitric Oxide Inhalation for Management of Right Ventricular Failure After Heart Transplantation in Patients With Pretransplant Pulmonary Hypertension,&quot; <i>Transplant Proc</i>, 1999, 31(6):2505-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/10500690/pubmed\" target=\"_blank\" id=\"10500690\">10500690</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peliowski A; Canadian Paediatric Society, Fetus and Newborn Committee. Inhaled nitric oxide use in newborns. <i>Paediatr Child Health</i>. 2012;17(2):95-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/23372402/pubmed\" target=\"_blank\" id=\"23372402\">23372402</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rich S, Kaufmann E, and Levy PS, &ldquo;The Effect of High Doses of Calcium-channel Blockers on Survival in Primary Pulmonary Hypertension,&rdquo; <i>N Engl J Med,</i> 1992, 327(2):76-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/nitric-oxide-drug-information/abstract-text/1603139/pubmed\" target=\"_blank\" id=\"1603139\">1603139</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ware AM, Golombek SG. Weaning of inhaled nitric oxide: is there a best strategy? <i>J Pediatr Neonat Individual Med</i>. 2015;4(1):e040124.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9447 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F201946\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F201947\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F201958\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F7730323\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F201952\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20210501\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20210502\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F201929\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F201914\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F49192472\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F201931\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F201930\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730874\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F201921\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F201934\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F201918\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299766\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F201923\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F201925\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F201937\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F201938\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F201927\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F201917\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F201933\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F201939\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9447|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=nitric-oxide-patient-drug-information\" class=\"drug drug_patient\">Nitric oxide: Patient drug information</a></li><li><a href=\"topic.htm?path=nitric-oxide-pediatric-drug-information\" class=\"drug drug_pediatric\">Nitric oxide: Pediatric drug information</a></li></ul></div></div>","javascript":null}